Sage Therapeutics Reports Results From Phase 2 LIGHTWAVE Study Of Dalzanemdor (SAGE-718); Says Did Not Show Statistically Significant Difference From Baseline In Participants Treated With Dalzanemdor Versus Placebo On Primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
Sage Therapeutics announced that its Phase 2 LIGHTWAVE study of dalzanemdor (SAGE-718) did not meet the primary endpoint, leading to the decision to halt further development for Alzheimer's Disease. However, results from another study on Huntington's Disease are expected later this year.

October 08, 2024 | 10:32 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics' Phase 2 study of dalzanemdor did not show significant results, leading to the halt of its development for Alzheimer's Disease. This could negatively impact the stock in the short term.
The failure to achieve statistically significant results in the Phase 2 study is a setback for Sage Therapeutics, as it halts further development of dalzanemdor for Alzheimer's Disease. This is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100